{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:40:10Z","timestamp":1743504010608,"version":"3.40.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangxi Natural Science Foundation","award":["2022GXNSFBA035481"],"award-info":[{"award-number":["2022GXNSFBA035481"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02214-x","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:00:40Z","timestamp":1743501640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic implications of alternative splicing events and key splicing factors in head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Siyi","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2214_CR1","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today[EB\/OL].  Lyon: International Agency for Research on Cancer, 2020. https:\/\/gco.iarc.fr\/today\/en. Accessed 1 May 2023."},{"issue":"10318","key":"2214_CR2","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/s0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer. Lancet. 2021;398(10318):2289\u201399. https:\/\/doi.org\/10.1016\/s0140-6736(21)01550-6.","journal-title":"Lancet"},{"issue":"11","key":"2214_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","volume":"16","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Le QT, et al. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669\u201383. https:\/\/doi.org\/10.1038\/s41571-019-0227-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2214_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092210","author":"F Perri","year":"2021","unstructured":"Perri F, Longo F, Fusco R, et al. Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx PDL-1 negative and\/or with evident contraindication to immunotherapy: a randomized multicenter controlled trial. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13092210.","journal-title":"Cancers"},{"issue":"1","key":"2214_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10006-021-00969-5","volume":"26","author":"G Salzano","year":"2022","unstructured":"Salzano G, Dell\u2019aversana Orabona G, Abbate V, et al. The prognostic role of the pre-treatment neutrophil to lymphocyte ratio (NLR) and tumor depth of invasion (DOI) in early-stage squamous cell carcinomas of the oral tongue. Oral Maxillofac Surg. 2022;26(1):21\u201332. https:\/\/doi.org\/10.1007\/s10006-021-00969-5.","journal-title":"Oral Maxillofac Surg"},{"key":"2214_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2023.06.003","volume":"259","author":"SL Jing","year":"2023","unstructured":"Jing SL, Afshari K, Guo ZC. Inflammatory response-related genes predict prognosis in patients with HNSCC. Immunol Lett. 2023;259:46\u201360. https:\/\/doi.org\/10.1016\/j.imlet.2023.06.003.","journal-title":"Immunol Lett"},{"issue":"24","key":"2214_CR7","doi-asserted-by":"publisher","first-page":"14957","DOI":"10.18632\/aging.205323","volume":"15","author":"Z Li","year":"2023","unstructured":"Li Z, Zheng C, Liu H, et al. A novel oxidative stress-related gene signature as an indicator of prognosis and immunotherapy responses in HNSCC. Aging. 2023;15(24):14957\u201384. https:\/\/doi.org\/10.18632\/aging.205323.","journal-title":"Aging"},{"issue":"4","key":"2214_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00432-024-05731-4","volume":"150","author":"L Wang","year":"2024","unstructured":"Wang L, He Y, Bai Y, et al. Construction and validation of a folate metabolism-related gene signature for predicting prognosis in HNSCC. J Cancer Res Clin Oncol. 2024;150(4):198. https:\/\/doi.org\/10.1007\/s00432-024-05731-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2214_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1631\/jzus.B2100512","volume":"23","author":"GS Zhang","year":"2022","unstructured":"Zhang GS, Wang Q, Qi XL, et al. OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information. J Zhejiang Univ-Sci B. 2022;23(3):249\u201357. https:\/\/doi.org\/10.1631\/jzus.B2100512.","journal-title":"J Zhejiang Univ-Sci B"},{"issue":"5","key":"2214_CR10","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1002\/jcp.29357","volume":"235","author":"ST Zhang","year":"2020","unstructured":"Zhang ST, Wu X, Diao PF, et al. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma. J Cell Physiol. 2020;235(5):4804\u201313. https:\/\/doi.org\/10.1002\/jcp.29357.","journal-title":"J Cell Physiol"},{"issue":"6","key":"2214_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nsmb.1608","volume":"16","author":"JP Venables","year":"2009","unstructured":"Venables JP, Klinck R, Koh C, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol. 2009;16(6):670-U98. https:\/\/doi.org\/10.1038\/nsmb.1608.","journal-title":"Nat Struct Mol Biol"},{"key":"2214_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canlet.2017.02.016","volume":"393","author":"Y Li","year":"2017","unstructured":"Li Y, Sun N, Lu ZL, et al. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017;393:40\u201351. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.016.","journal-title":"Cancer Lett"},{"issue":"1","key":"2214_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12864-023-09325-1","volume":"24","author":"C Lin","year":"2023","unstructured":"Lin C, Chen YB, Pan JJ, et al. Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma. BMC Genom. 2023;24(1):16. https:\/\/doi.org\/10.1186\/s12864-023-09325-1.","journal-title":"BMC Genom"},{"key":"2214_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/bcj.2017.71","volume":"7","author":"SK Leivonen","year":"2017","unstructured":"Leivonen SK, Taskinen M, Cervera A, et al. Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma. Blood Cancer J. 2017;7:10. https:\/\/doi.org\/10.1038\/bcj.2017.71.","journal-title":"Blood Cancer J"},{"issue":"10","key":"2214_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/genes8100217","volume":"8","author":"N Mart\u00ednez-Montiel","year":"2017","unstructured":"Mart\u00ednez-Montiel N, Anaya-Ruiz M, P\u00e9rez-Santos M, et al. Alternative splicing in breast cancer and the potential development of therapeutic tools. Genes. 2017;8(10):14. https:\/\/doi.org\/10.3390\/genes8100217.","journal-title":"Genes"},{"issue":"3","key":"2214_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1159\/000492094","volume":"48","author":"RQ He","year":"2018","unstructured":"He RQ, Zhou XG, Yi QY, et al. Prognostic signature of alternative splicing events in bladder urothelial carcinoma based on spliceseq data from 317 cases. Cell Physiol Biochem. 2018;48(3):1355\u201368. https:\/\/doi.org\/10.1159\/000492094.","journal-title":"Cell Physiol Biochem"},{"key":"2214_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ebiom.2018.07.040","volume":"34","author":"P Lin","year":"2018","unstructured":"Lin P, He RQ, Ma FC, et al. Systematic analysis of survival-associated alternative splicing signatures in gastrointestinal pan-adenocarcinomas. EBioMedicine. 2018;34:46\u201360. https:\/\/doi.org\/10.1016\/j.ebiom.2018.07.040.","journal-title":"EBioMedicine"},{"key":"2214_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-018-0115-2","volume":"8","author":"YT Yang","year":"2018","unstructured":"Yang YT, Chiu YC, Kao CJ, et al. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. Blood Cancer J. 2018;8:11. https:\/\/doi.org\/10.1038\/s41408-018-0115-2.","journal-title":"Blood Cancer J"},{"key":"2214_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fgene.2019.00278","volume":"10","author":"D Zhang","year":"2019","unstructured":"Zhang D, Duan Y, Cun JJ, et al. Identification of prognostic alternative splicing signature in breast carcinoma. Front Genet. 2019;10:20. https:\/\/doi.org\/10.3389\/fgene.2019.00278.","journal-title":"Front Genet"},{"issue":"2","key":"2214_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ygyno.2017.11.028","volume":"148","author":"JY Zhu","year":"2018","unstructured":"Zhu JY, Chen ZH, Yong L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 2018;148(2):368\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.028.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2214_CR21","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.7150\/ijbs.58888","volume":"17","author":"K Li","year":"2021","unstructured":"Li K, Wang ZQ. Splicing factor SRSF2-centric gene regulation. Int J Biol Sci. 2021;17(7):1708\u201315. https:\/\/doi.org\/10.7150\/ijbs.58888.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"2214_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms24076055","volume":"24","author":"M Choudhry","year":"2023","unstructured":"Choudhry M, Gamallat Y, Kish EK, et al. Downregulation of BUD31 promotes prostate cancer cell proliferation and migration via activation of p-AKT and vimentin in vitro. Int J Mol Sci. 2023;24(7):14. https:\/\/doi.org\/10.3390\/ijms24076055.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2214_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41467-022-34042-w","volume":"13","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Wang SR, Qin JC, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat Commun. 2022;13(1):18. https:\/\/doi.org\/10.1038\/s41467-022-34042-w.","journal-title":"Nat Commun"},{"issue":"1","key":"2214_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60\u201372. https:\/\/doi.org\/10.1056\/NEJMra1715715.","journal-title":"N Engl J Med"},{"key":"2214_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oraloncology.2019.04.019","volume":"93","author":"G Troiano","year":"2019","unstructured":"Troiano G, Caponio VCA, Adipietro I, et al. Prognostic significance of CD68+ and CD163+ tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2019;93:66\u201375. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.04.019.","journal-title":"Oral Oncol"},{"key":"2214_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.1099835","volume":"13","author":"LL Fu","year":"2022","unstructured":"Fu LL, Yan M, Ma MX, et al. DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma (Vol 13, 939344, 2022). Front Immunol. 2022;13:1. https:\/\/doi.org\/10.3389\/fimmu.2022.1099835.","journal-title":"Front Immunol"},{"issue":"1","key":"2214_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ygeno.2020.12.002","volume":"113","author":"ZH Wu","year":"2021","unstructured":"Wu ZH, Zhong Y, Zhou T, et al. miRNA biomarkers for predicting overall survival outcomes for head and neck squamous cell carcinoma. Genomics. 2021;113(1):135\u201341. https:\/\/doi.org\/10.1016\/j.ygeno.2020.12.002.","journal-title":"Genomics"},{"issue":"9","key":"2214_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ijms22094981","volume":"22","author":"T Magnes","year":"2021","unstructured":"Magnes T, Wagner S, Kiem D, et al. Prognostic and predictive factors in advanced head and neck squamous cell carcinoma. Int J Mol Sci. 2021;22(9):16. https:\/\/doi.org\/10.3390\/ijms22094981.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2214_CR29","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1101\/gad.1973010","volume":"24","author":"CJ David","year":"2010","unstructured":"David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010;24(21):2343\u201364. https:\/\/doi.org\/10.1101\/gad.1973010.","journal-title":"Genes Dev"},{"issue":"13","key":"2214_CR30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2174\/1381612043384808","volume":"10","author":"C Ebbinghaus","year":"2004","unstructured":"Ebbinghaus C, Scheuermann J, Neri D, et al. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, A marker of tumor angiogenesis. Curr Pharm Design. 2004;10(13):1537\u201349. https:\/\/doi.org\/10.2174\/1381612043384808.","journal-title":"Curr Pharm Design"},{"issue":"4","key":"2214_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1053\/j.gastro.2005.07.025","volume":"129","author":"S Sato","year":"2005","unstructured":"Sato S, Idogawa M, Honda K, et al. \u03b2-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. Gastroenterology. 2005;129(4):1225\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2005.07.025.","journal-title":"Gastroenterology"},{"issue":"1","key":"2214_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1158\/1541-7786.53.2.1","volume":"2","author":"S Solier","year":"2004","unstructured":"Solier S, Lansiaux A, Logette E, et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004;2(1):53\u201361.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2214_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/15476286.2022.2113148","volume":"19","author":"SZ Wang","year":"2022","unstructured":"Wang SZ, Wang SY, Zhang X, et al. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer. RNA Biol. 2022;19(1):1007\u201318. https:\/\/doi.org\/10.1080\/15476286.2022.2113148.","journal-title":"RNA Biol"},{"key":"2214_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fonc.2021.713017","volume":"11","author":"SS Liu","year":"2021","unstructured":"Liu SS, Zhao W, Li XM, et al. AGTRAP is a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Front Oncol. 2021;11:15. https:\/\/doi.org\/10.3389\/fonc.2021.713017.","journal-title":"Front Oncol"},{"issue":"19","key":"2214_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cells11193141","volume":"11","author":"XY Cui","year":"2022","unstructured":"Cui XY, Pei XS, Wang H, et al. ALG3 promotes peritoneal metastasis of ovarian cancer through increasing interaction of \u03b11,3-mannosylated uPAR and ADAM8. Cells. 2022;11(19):18. https:\/\/doi.org\/10.3390\/cells11193141.","journal-title":"Cells"},{"issue":"1","key":"2214_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-021-01932-8","volume":"40","author":"XQ Sun","year":"2021","unstructured":"Sun XQ, He ZY, Guo L, et al. ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-\u03b2 receptor II in breast cancer. J Exp Clin Cancer Res. 2021;40(1):25. https:\/\/doi.org\/10.1186\/s13046-021-01932-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"2214_CR37","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.12659\/msm.907461","volume":"24","author":"YD Yang","year":"2018","unstructured":"Yang YD, Zhou YL, Xiong X, et al. ALG3 is activated by heat shock factor 2 and promotes breast cancer growth. Med Sci Monitor. 2018;24:3479\u201387. https:\/\/doi.org\/10.12659\/msm.907461.","journal-title":"Med Sci Monitor"},{"key":"2214_CR38","unstructured":"Zhang C-C, DW-M. Gene expression profiling reveals important characteristic genes in hepatocellular carcinoma. J Tianjin Med Univ. 2020;26(06):514\u20137."},{"issue":"03","key":"2214_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.16695\/j.cnki.1006-2947.2019.03.029","volume":"25","author":"H-Y Cao","year":"2019","unstructured":"Cao H-Y, Wang L, Li Q-C. Mechanism of CCDC family proteins promoting malignant progression of tumor. Prog Anat Sci. 2019;25(03):335\u20138. https:\/\/doi.org\/10.16695\/j.cnki.1006-2947.2019.03.029.","journal-title":"Prog Anat Sci"},{"issue":"01","key":"2214_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.19401\/j.cnki.1007-3639.2022.01.002","volume":"32","author":"L Yi","year":"2022","unstructured":"Yi L, Ce W, Xun K, Zhuang K, Feng C, Bo J, Wenbin L. Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis. China Oncol. 2022;32(01):13\u201323. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2022.01.002.","journal-title":"China Oncol"},{"issue":"4","key":"2214_CR41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1538-7445.AM2015-1460","volume":"5","author":"Q Li","year":"2015","unstructured":"Li Q, Yao L, Wei Y, et al. Role of RHOT1 on migration and proliferation of pancreatic cancer. Am J Cancer Res. 2015;5(4):1460\u201370.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2214_CR42","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1080\/21655979.2022.2036514","volume":"13","author":"YY Peng","year":"2022","unstructured":"Peng YY, Sun D, Xin Y. Hsa_circ_0005230 is up-regulated and promotes gastric cancer cell invasion and migration via regulating the miR-1299\/RHOT1 axis. Bioengineered. 2022;13(3):5046\u201363. https:\/\/doi.org\/10.1080\/21655979.2022.2036514.","journal-title":"Bioengineered"},{"issue":"03","key":"2214_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.19401\/j.cnki.1007-3639.2022.01.002","volume":"38","author":"C Chen","year":"2023","unstructured":"Chen C. Expression of ABCC5 in hepatocellular carcinoma and lts clinical significance based on bioinformatic database. Pract J Cancer. 2023;38(03):402\u20136. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2022.01.002.","journal-title":"Pract J Cancer"},{"key":"2214_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cddis.2017.53","volume":"8","author":"YX Hou","year":"2017","unstructured":"Hou YX, Zhu QL, Li Z, et al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017;8:11. https:\/\/doi.org\/10.1038\/cddis.2017.53.","journal-title":"Cell Death Dis"},{"issue":"05","key":"2214_CR45","doi-asserted-by":"publisher","first-page":"877","DOI":"10.16190\/j.cnki.45-1211\/r.2023.05.024","volume":"40","author":"W Junping","year":"2023","unstructured":"Junping W, Xiaofeng T, Guirong M, Zuyun L. Expression and clinical significance of ABCC5 in lung squamous cell carcinoma. J Guangxi Med Univ. 2023;40(05):877\u201383. https:\/\/doi.org\/10.16190\/j.cnki.45-1211\/r.2023.05.024.","journal-title":"J Guangxi Med Univ"},{"issue":"10","key":"2214_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/biom11101492","volume":"11","author":"JH Jung","year":"2021","unstructured":"Jung JH, Lee D, Ko HM, et al. Inhibition of CNOT2 induces apoptosis via MID1IP1 in colorectal cancer cells by activating p53. Biomolecules. 2021;11(10):9. https:\/\/doi.org\/10.3390\/biom11101492.","journal-title":"Biomolecules"},{"issue":"10","key":"2214_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers11101470","volume":"11","author":"J Lee","year":"2019","unstructured":"Lee J, Jung JH, Hwang J, et al. CNOT2 is critically involved in atorvastatin induced apoptotic and autophagic cell death in non-small cell lung cancers. Cancers. 2019;11(10):15. https:\/\/doi.org\/10.3390\/cancers11101470.","journal-title":"Cancers"},{"issue":"12","key":"2214_CR48","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/2211-5463.12998","volume":"10","author":"B Zhang","year":"2020","unstructured":"Zhang B, Han S, Ma HT, et al. CNOT4 enhances the efficacy of anti-PD-1 immunotherapy in a model of non-small cell lung cancer. FEBS Open Bio. 2020;10(12):2631\u20139. https:\/\/doi.org\/10.1002\/2211-5463.12998.","journal-title":"FEBS Open Bio"},{"issue":"1","key":"2214_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41598-020-73700-1","volume":"10","author":"LB Wang","year":"2020","unstructured":"Wang LB, Wang YY, Su B, et al. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study. Sci Rep. 2020;10(1):16. https:\/\/doi.org\/10.1038\/s41598-020-73700-1.","journal-title":"Sci Rep"},{"issue":"5","key":"2214_CR50","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s13402-023-00807-8","volume":"46","author":"TY Feng","year":"2023","unstructured":"Feng TY, Li SQ, Zhao G, et al. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. Cell Oncol. 2023;46(5):1235\u201352. https:\/\/doi.org\/10.1007\/s13402-023-00807-8.","journal-title":"Cell Oncol"},{"issue":"1","key":"2214_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-022-01096-7","volume":"7","author":"G Zhao","year":"2022","unstructured":"Zhao G, Yuan H, Li Q, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. Signal Transduct Target Ther. 2022;7(1):15. https:\/\/doi.org\/10.1038\/s41392-022-01096-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2214_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.heliyon.2022.e08994","volume":"8","author":"XY Li","year":"2022","unstructured":"Li XY, Yang L, Huang W, et al. Immunological significance of alternative splicing prognostic signatures for bladder cancer. Heliyon. 2022;8(2):12. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e08994.","journal-title":"Heliyon"},{"issue":"19","key":"2214_CR53","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1093\/hmg\/dds266","volume":"21","author":"AL Stark","year":"2012","unstructured":"Stark AL, Delaney SM, Wheeler HE, et al. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012;21(19):4348\u201355. https:\/\/doi.org\/10.1093\/hmg\/dds266.","journal-title":"Hum Mol Genet"},{"key":"2214_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fgene.2022.989081","volume":"13","author":"F Ye","year":"2022","unstructured":"Ye F, Wu PA, Zhu YQ, et al. Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma. Front Genet. 2022;13:16. https:\/\/doi.org\/10.3389\/fgene.2022.989081.","journal-title":"Front Genet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02214-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:00:58Z","timestamp":1743501658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02214-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2214"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02214-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that the animal experiments were carried out following the rules of the Basel Declaration. The study was approved by the Ethics Committee for Animal Use at the Guangxi Medical University (NO.: 202401017). According to the committee's guidelines, the tumor burden should not exceed 5% of the animal's normal body weight, and the tumor diameter should not exceed 15\u00a0mm. The tumor size in the animal models used in this study was well within these limits, ensuring compliance with the ethical standards. TCGA belongs to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open source data, so there are no ethical issues and other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}